Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effet of pioglitazone and darglitazone on AML cell lines

ABSTRACT: Effet of pioglitazone and darglitazone on AML cell lines

PROVIDER: PRJNA1018972 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26114181_1.fastq.gz	Fastqsanger.gz
	SRR26114181_2.fastq.gz	Fastqsanger.gz
	SRR26114182_1.fastq.gz	Fastqsanger.gz
	SRR26114182_2.fastq.gz	Fastqsanger.gz
	SRR26114183_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Effet of pioglitazone and darglitazone on AML cell lines

Project description:As PPAR-gamma is a nuclear receptor acting as a transcription factor regulating the expression of multiple genes and to better understand the signaling pathways involved, we performed RNAseq analysis on AML cell lines cultured in the absence or presence of pioglitazone or darglitazone.

2024-09-30 | GSE243586 | GEO

Metabolomics Workbench ST000288 - GNPS - Metabolomic profiling of AML Cell Lines

Project description:In vitro study with AML cell lines that are treated with different concentrations of cytarabine (nucleoside analog). 8 AML cell lines were incubated for 24hr with 0uM, 1uM and 10uM ara-C. After 24hr the cells were washed and pellets were stored in -80°C for genomic and metabolomic analysis.

2018-08-02 | MSV000082685 | GNPS

Metabolomic profiling of AML Cell Lines

2015-02-15 | ST000288 | MetabolomicsWorkbench

CUT-TAG for AML cell lines

Project description:CUT-TAG for AML cell lines

| PRJNA1032018 | ENA

Expression data from human AML cell lines

Project description:Expression data from human AML cell lines

| PRJNA604259 | ENA

Human AML cell lines LC-MS/MS - Performance of Super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines

Project description:As a direct consequence of the high diversity of the aggressive blood cancer acute myeloid leukemia (AML), proteomic samples from patients are strongly heterogeneous, rendering their accurate relative quantification challenging. In the present study, we investigated the benefits of using a super-SILAC mix of AML derived cell lines as internal standard for quantitative shotgun studies. The Molm-13, NB4, MV4-11, THP-1, and OCI-AML3 cell lines were selected for their complementarity with regard to clinical, cytogenetic and molecular risk factors used for prognostication of AML patients. The resulting internal standard presents a high coverage of the AML proteome compared to single cell lines allied with high technical reproducibility, thus enabling its use for AML patient comparison. This was confirmed by comparing the protein regulation between the five cell lines and applying the internal standard to patient material.

2014-07-15 | PXD000441 | Pride

Single-shot proteome of AML cell lines and AML ex vivo cells upon selinexor treatment

Project description:Single-shot proteome analysis of 4 AML cell lines; 2 selinexor sensitive cell lines (GDM-1, MV4-11) and 2 resistant cell lines (NOMO-1 and PL-21) and ex vivo AML cells from 30 patients treated with DMSO (B; before treatment) or 1 uM selinexor (A; after treatment) for 6 hours.

2022-08-07 | PXD033515 | Pride

Transcriptomic profiling of human AML cell lines and primary AML samples

Project description:Transcriptomic profiling of human AML cell lines and primary AML samples

| PRJNA952616 | ENA

Transcriptomic profiling of human AML cell lines and primary AML samples

Project description:We sequenced mRNA from both cell lines and primary samples to investigate transcriptomic profiles of human AML cell lines and primary samples. We then performed gene expression profiling analysis using data obtained from RNA-seq of AML cell lines and primary samples that have sphingolipidomic characterization to identify transcriptional differences between two distinct sphingolipidomic subtypes in AML samples.

2024-01-14 | GSE229032 | GEO

The phosphoproteomic landscape of 16 Acute Myeloid Leukemia (AML) cell lines

Project description:Acute myeloid leukemia (AML) is a clonal hematopoietic malignancy, characterized by expansion of immature leukemic blasts in the bone marrow. In AML, specific tyrosine kinases have been implicated in leukemogenesis, and are associated with poor treatment outcome. However, targeted therapy using kinase inhibitors (KIs) has had limited success, and may be improved by proper patient selection. We performed phosphotyrosine (pY) based, label-free phosphoproteomics to identify hyperphosphorylated, active kinases in AML cell lines as targets and predictive biomarkers to select KIs for treatment. We identified 3605 class I phosphorylation sites in 16 AML cell lines (EOL-1, KG-1a, MM6, KG-1, ME-1, NB-4, Kasumi-3, MV4-11, THP-1, HEL, HL-60, Kasumi-1, Kasumi-6, ML-2, OCI-AML3, MOLM-13) that exhibited large variation in the number and level of phosphopeptides per cell line (241-2764). Ranking analyses successfully pinpointed the hyperactive kinases PDGFRA, FGFR1, KIT, and FLT3 in eight cell lines with a corresponding kinase mutation. Additionally, we identified unexpected drivers in two more cell lines (PDGFRA in Kasumi-3 and FLT3 in MM6) which proved sensitive to specific kinase inhibitors. Six cell lines without a clear receptor tyrosine kinase (RTK) driver showed evidence of MAPK1/3 activation, consistent with the presence of activating RAS mutations. Our data show the potential of pY phosphoproteomics to identify key drivers in AML cells, and the predictive value of the phosphoproteome profiles in TKi selection for targeted treatment.

2019-11-11 | PXD007237 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data